The OU Health Board of Directors on Feb. 4 announced Richard Lofgren, MD, MPH, FACP, as CEO of OU Health, Oklahoma’s only integrated, comprehensive academic health system.
Drug developed to suppress cancerous tumors also has ability to lower blood sugar levels that were elevated due to obesity and Type 2 diabetes.
Researcher at Harold Hamm Diabetes Center receives $1.6 million NIH grant to better understand how non-alcoholic fatty liver disease (NASH).
OU Health to receive more than $1 million to participate in a National Institutes of Health (NIH) initiative to better understand long-term effects of COVID-19 infection.